In other recent news, CVS Health has agreed to a $12.25 million settlement with Massachusetts over allegations of overcharging the state's Medicaid program, MassHealth. The settlement addresses claims that CVS charged higher prices to MassHealth compared to discounts available to cash-paying customers. In the realm of stock analysis, Cantor Fitzgerald has reiterated its Overweight rating for CVS Health, setting a price target of $78, while Jefferies also maintained a Buy rating with a target of $80. These ratings come as the company navigates ongoing changes in the health insurance marketplace and investor concerns ahead of its second-quarter financial results. Meanwhile, CVS Caremark, a major pharmacy benefit manager, has decided not to include Gilead Sciences' new HIV prevention drug Yeztugo in its commercial plans. This decision was based on clinical, financial, and regulatory factors, as stated by a CVS spokesperson.